DLBCL clinical trials at UC Health
2 in progress, 1 open to eligible people
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
open to eligible people ages 18 years and up
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).
Sorry, in progress, not accepting new patients
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.